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Frontal lobe dysfuncti on in schizo ph ren ic pa tients has been high ly sus-
pected for many years. Man y psychiatrists a nd patients, however, are awai ting
so lid p roof of a biological manifesta tion of th is disease. While positron emission
tomography does not uniformly demonstrate suc h a mani festa tion , it does
demonstrate a prefrontal cortex deficit in most reported studies . Furthe r , a
locali zation of the attention deficit of sch izo phrenia, in the prefrontal co r tex, is
stro ngly suggeste d by some stud ies.
INTROD UC TION
Positron emiss io n tomography (PET) has e na b led investigators in modern
clin ica l psychiat r y to demonstrate that schizoph renia is, at least in part , a frontal
lobe di sorder. PET studies of many pati ents with sch izophren ia exh ibit a
decrea sed level of metaboli sm in the frontal cortex. O th er brain areas have also
been in vestigat ed fo r th ei r role in schizo ph renia. T hese regions include the
hippocampus ( I), ba sal ganglia, limbic system, and other brainstem areas (2) .
This re view , however, is limited to the deficit most co nsis te n t ly reported with
PET brain metaboli sm stud ies-hypofronta lity .
Frontal lobe d ysfunction in schizoph ren ia has been suggested fo r many
years by several research paradigms. Post-mortem studies ha ve reported abnor-
mal neurotransmitter rece ptor levels including se rotonergic (3,4), muscarinic
(5) , GABAergic (6), and others. Histological abnor malit ies in the frontal co rt ex
of schizop hrenic pati ents, includi ng decreased cortical cells (neurons > glia) in
layer VI (7) a nd ultrastructural (EM) abnor malit ies in neurons (8), have bee n
reported. Frontal lobe pathology has a lso been suggested by MRI studies,
reporting sign ificantly sm all er frontal lobes in schizop hrenics (9) . Cogniti ve
aspects ofsch izo ph renia, includi ng attention a nd vigi lance, have been a cont inu-
ing foc us in th e evalua tion of this di sease (10, II ). A recent study of patients with
fronta l lobe lesions demonstrated that these pati ents also had a deficiency in
maintaining tasks that require sus ta ined attention (12). Fro ntal lobe d ysfunct ion
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in schizop h re nia has, th erefore , been strongly suggested from several research
paradigms. Recently, however, a locali zation of this deficit in a specific brain
region has been demonstrated by funct ional imaging techniques.
Early functional imaging stud ies of cerebral metabolism uti lized Xe [133]
inhalation or carotid injection to examine relative blood flow rates. Ingva r and
Frazen applied this technology to the study of schizophrenic patient s and
demonstrated a relative decrease in ce rebral blood flow in th ese patients (13 ,14).
They reported that normal persons demonstrated a relatively higher b lood flow
in th e prefrontal cortex than in temporal or parietal cor t icies. In schizophrenic
patients, however, this hyperfrontal ity was attenua te d and th e patients were
described as hypofr ontal. A review of attempts to replicat e these findings is
available (15). Cerebral blood flow stud ies using Xe [133 ], however , have seve ral
limitations, including lower spatial resolution and provision of on ly relative
blood flow values. PET scan technology has been useful in co nfirming, and
investigating more effectively, hypofrontality in schizop hren ia. Recent advances
in contro lling the behavioral aspects of the scanning procedure and evidence of
a more precise localization of the dysfunction in th e mid-prefron tal cortex may
permit significant advances in th e understanding of schizophrenia (16).
PET TECHNOLOGY
PET scanning utilizes shor t lived, radioacti vely labeled biomolecules to
study normal and diseased states in brain tissues. A positron emi tt ing isotope is
incorporated into metabolites, or drugs, by using a cyclo tron wh ich forms an
unstable nucleus. Within the nucleus of the isotope, a proton tran sforms into a
neutron . During this transformation, a positron is emitted . T he posit ron then
collides with an electron to produce two photons of light. A geometr ica l image
of relative photon activity is then developed. A detailed review of PET technol-
ogy is available (17 ).
One of the most useful compounds in psychiatric research has been F[ 18]-
labeled 2 f1ouro-2-deoxy-D glucose (FDG). The FDG tracer meth od , developed
by Sokoloff, Re ivich and coworkers (18-20), has been used to evaluate glucose
metabolism in brain tissues. According to their 2-d eoxyglucose model , FDG is
transported into the cell and phosphorylated in a manner simi lar to glucose .
However, unlike glucose, phosphorylated FDG is not a subst rat e for metaboli sm .
Once transported into the cell , FDG is phosphorylated and degraded slowly
enough to be considered essentially trapped during th e sca nn ing measu rement s.
FDG is phosphorylated (the rate limiting step) ba sed on metabol ic needs and is,
therefore, a good indicator of cellular ac tivity . The func t ional imaging offered
by PET opens new dimensions in the study of brain physiology. Although
conventio na l imaging with x-ray technology ha s ena b led visua liza tion of struc-
tural changes (eg. ventricular enlargement) in schizophrenia, PET may detect
biochemical changes at an earlier stage and provide more information about th e
pathophysiology.
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T A BLE 1.
SICStudy
Pet Studies of Frontal Cortex Metabolism in Schizophrenic P atien ts Off Medication
Frontal
Met abol ism
Differences
Farkas, et ai, 1980 (21 )
Buchsbaum, et ai, 198 1 (22)
Buch sbaum, et ai, 1982 (29)
Sheppard , et ai , 1983 (30)
Widen, et aI, 198 3 (3 1)
Brodi e , et ai, 1984 (32)
Buchsbaum, e t ai, 1984 (33, 34)
Buchsbaum, et a i, 1984 (35)
DeLisi, et ai, 1985 (36)
Jernigan, et ai, 1985 (37)
Wo lkin, et a i, 1985 (38)
Sedvall , et ai, 1986 (39)
Volkow, et al, 1986 (40)
Cohen, et ai, 1987 (16)
Early, etal,1987(4 1)
Cur, et ai , 1987 (42)
Wiessel, e t al, 1987 (43)
Wolkin , et ai, 1987 (44)
Wolkin, et al , 1988 (45)
DeLisi, et ai, 1989 (46)
Cur, et ai, 1989 (47)
I /n.r.
5/5
8/6
12/ 12
6/ 12
6/5
16/19
4/19
20 /21
6/6
10/8
13/10
4/12
16/27
10/20
12/12
10/20
6/9
13/8
2 1/9
20 /18
decreased
decreased
decreased
nonsigni fican t
decreased
decreased
decreased
decreased
decreased
nonsign ificant
nonsignificant
inc reased
nonsignificant
decreased
no nsignificant
nonsignificant
decreased*
decreased
decreased
no nsignificant
no nsignificant
Symbols: SIC - Schizophrenic patients/ co ntro l subjects; *o nly stu dy reporting decreased
frontal rate, ye t increased A:P ratio; n.r. - not repor ted.
Notes: I) All studies used age-matched controls except Buchsbaum , 1984 (quadruplet
study - ages 51); Wolkin, 1985 (mean ages sic - 38 /27). Brodie , 1984 , d id not report
ages. All remaining st udies reported mean ages of22-38 .
2) Frontal metabolism differences include reported differences in abso lu te frontal rates;
fronta l: whole slice, fronta l: whole brain or anterior:posterior ratios.
3) All stu dies used glucose ligands excep t Sheppard, 1984 (O[ 15 ] and C[ 15]02).
DEM ONSTRATION O F HYPOFRONTALITY BY PET
A search of PET literature reporting on frontal lobe glucose metaboli sm in
schizophrenic patients uncovered approximately thirty studies . The first PET
repor t of hypometabolic activity in the frontal cortex of a sch izop hren ic pati ent
was by Farkas, Re ivich and coworkers in 1980 (21). Other ea rly stu dies by
Buchsbaum (22) and Widen (23) confirmed the evidence of hypofr ontal ity.
St udies using medicated schizophrenic patients have generally demonst rated
hypometaboli c ac tiv ity in the frontal cortex (24-28). Table I , above , however ,
presents a review of 2 1 studies using only unmedicated and never medicated
patients, due to a concern of possible confounding effec t by neu roleptic treat-
ment . Review of these stud ies revea ls some inconsistent findin gs. Several vari-
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abies have been conside red as possible sources for th e discrepa ncy between these
findings.
The variable which has received the most discussion in the lite ra ture has
been neuroleptic treatment. Some investigators have questioned the validity of
reports of hypometabolic activity in the frontal cortex of schizophre nics because
of neuroleptic treatment concurrent with or preceding sca nn ing proced ures
(30 ,4 1). These investigators suggest that hypofrontal ity findings may be an
effect of treatment and not a manefestation of schizophren ia. T h is view is partly
supported by findings of extended clinical and pharmacokineti c effects which
persist following termination of medication (48, 49) . Additional support for their
viewpoint comes from studies of never-medicated schizophrenics (30,3 1,40,41 ).
These studies have consistently found no sign ificant differences in fronta l lobe
metabolism in schizophrenic patients. However, these findi ngs may be due to a
biological difference between new-onset and chronic sch izop hrenia. A recent
report by Wiessel and coworkers (43) indicated that duration of illness was
directly correlated with degree ofhypofrontality.
Due to the concern of possible frontal lobe changes with ne uroleptic
treatment, most studies have utilized patients whi ch have been tak en off medica-
tion prior to th e scanning procedure (wash-out studies). Of th e recent studies
using non medicated patients (see table) , most have used patients off ne urol eptics
fo r at least 13 days. Some studies have used wash-out periods of only 10 da ys
(44, 45). Others have used mixed samples with some patients that rece ived
limited dosages at least forty-eight hours prior to scanning (30) or some pat ients
off neuroleptics for at least seven days (42). One study did not specify durat ion
off medication (22).
Support for the validity of studies reporting hypofrontality in pa tients
unmedicated prior to and during scanning procedures ca n be fo und in the
reports of PET studies comparing metabolism before and during neurolept ic
treatment. These reports have generally indicated that frontal glucose me tab o-
lism is either unchanged or increased, not decreased, during neuroleptic treat-
ment (38-40 ,50-53). Changes in metabolism were stud ied with med ication
intervals ranging from 1 hour to 7.4 years. Further support for th e validity of
studies using previously medicated patients comes fr om dopamine receptor
occupancy studies. Using Br[76] labeled bromosp iperone b indin g to corpus
striatum, Camdon and coworkers (54) found that after neuroleptic withdrawal, a
return to 100% unoccupied receptors occurred within 7- 12 days in the majority
(6/ 8) of subjects tested. A final a nswe r to this quest ion of neuroleptic effects on
frontal lobe metabolism ma y require a prospective study of metaboli c rates
before, during and foll owing neuroleptic treatment, whi ch demo nstra tes a
com p le te return to ba seline metabolism.
One var iable of increasingly apparent importance, whi ch remains less than
opt imally contro lled in most experiments to dat e , is behavio ral activity during
PET scanning. Most studies of metabolic activity have used resting subjects.
Many stud ies have taken measures to limit senso ry st imu lation of the patient
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during scanning in order to provide a more uniform sensory envi ronment.
Other studies have used somatosensory stimuli in the form of mild electrica l
shock to the right forearm (33,34,36,50). Somatosensory stimuli have been used
to maintain a uniform sensory environment between subjects and preferentiall y
activate the frontal lobes (55,56). Xe [133] blood flow studies have reported
attenuation of this activation in schizophrenic subjects (57). However , a recent
PET study comparing sensory environments during scanning found that soma-
tosensory stimulation is not an effective method of frontal cortex acti vatio n (58).
In a study of 52 normal volunteers. Cohen and co-workers compared the effects
of somatosensory stimulation , auditory discrimination and resting sta tes on
frontal metabolic activity. Increased metabolic rates were found in th e r ight
middle prefrontal cortex during the auditory discrimination task. This increased
rate demonstrated a direct correlation with the accuracy of the subjects' perfo r-
mance, suggesting that this area may be very important in attention mainte-
nance. The somatosensory stimuli, however, was not associated with generali zed
activation of the frontal cortex.
Continuous performance tasks, such as the auditory di scrimination task,
have also been used to study the attention deficits in schizophrenia. Continuous
performance tasks have been shown to be highly sensitive to functi onal illness
(59) and have been used to demonstrate attention deficits in sch izophrenia (60).
Their attention deficit is evident in several areas. They often fail to attend to
novel stimuli (6 I). Once attention is attained, they often fail to ma intai n task
performance. The fronallobe appears to be involved in anticipatory responding.
The fronal lobe deficit theory of schizophrenia, therefore, is supported by th e
patient's poor preparation for response. A study by Cohen (16) examining 16
schizophrenic patients, performing auditory discrimination tasks during PET
scanning, demonstrated specific areas of deficient metabolism. O f the 55 specific
regions examined, only the left anterior, medial and right anterior areas of the
frontal cortex, in a single plane, demonstrated significant metabolic de ficits. An
earlier study by Jernigan and co-workers (37) also used an aud itory d iscr imina-
tion task to study schizophrenic patients. Their finding of nonsignificant cha nges,
however, may have been due to a limited sample size (6 pati ents) or th e limited
number of slices analyzed (I slice).
CONCLUSIONS
Greater than 50% of the PET studies investigating fr ontal lobe metabolism
have demonstrated decreased activity in schizophrenic patients. The var iabilit y
of findings in the frontal cortex do not appear to be caused by neuroleptic
medication. However, a prospective study of neuroleptic effec ts before , during
and after medication may be useful. Some authors have suggeste d that the
failure to consistently confirm frontal deficits may be due to different path ologi-
cal groups of schizophrenics (eg. frontal and temporal lesions). O thers have
suggested that variance between studies may reflect the chronicity of th e d isease .
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Additional sources of variance may include specificit y of analysis (eg. whole
frontal cortex slice vs. subdivided areas) and sample size. Frontal cortex ac tivat-
ing ta sks may also reduce the variability between studies by utilizing the recog-
nized attention deficit seen in most of these patients.
In summary, an area of metabolic dysfunction in the prefrontal co rtex of
schizophrenic patients has been demonstrated through th e use of posit ron
emission tomography. The inconsistencies in the attempts to replicat e th ese
findings are probably due to multiple variables. The fact th a t 50% of the studies
have succeeded in demonstrating a frontal lobe deficit is remark able , given th e
lack of frontal activating tasks and limited subdivision of frontal areas in most
studies.
In conclusion, PET technology is opening new dimensions to th e study of
psychiatric research. PET offers functional imaging not provid ed by previou s
analytical instruments and greater precision and depth than o ther newly devel-
oped techniques. Further refinement of nuclear and computer technology, and
experimental methodology promise to make PET an invaluable tool in the study
of schizophrenia and other mental diseases.
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